Tailored Covalency offers the potential to address a broad spectrum of immune-mediated diseases.
New medicines introduced over the past decade have improved clinical outcomes in certain diseases, but a considerable proportion of patients do not adequately respond to new treatments, some of which are associated with undesirable side effects and long-term consequences, and negatively impact the quality of life.
We believe that the treatment of immune-mediated diseases may ideally benefit from a more tailored approach, where an oral drug could deliver an improved risk benefit by selectively modulating the immune system while reducing off-target activity and/or long-term, irreversible, broad immunosuppression.
In pemphigus, a part of the skin structure is attacked. In immune thrombocytopenia (ITP) platelets are mistakenly attacked and destroyed. In multiple sclerosis, the brain and spinal cord become inflamed and damaged when attacked by the immune system. Thus, our focus is to target the immune dysfunction at the root of these diseases.